Adial Pharmaceuticals (NASDAQ:ADIL) Posts Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Adial Pharmaceuticals (NASDAQ:ADIL) released its earnings results on Tuesday. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.23, Zacks reports.

Adial Pharmaceuticals Stock Up 2.8 %

Shares of ADIL opened at $0.75 on Wednesday. The company’s 50 day moving average price is $0.90 and its 200 day moving average price is $0.99. Adial Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $3.10.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Rodman & Renshaw assumed coverage on shares of Adial Pharmaceuticals in a research report on Thursday, November 14th. They set a “buy” rating and a $8.00 price objective on the stock. RODMAN&RENSHAW raised shares of Adial Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.